Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular carcinoma

2022-500903-38-00 Protocol 38RC22.210 LIVERNET1 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 9 Feb 2023 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 12 sites · Protocol 38RC22.210 LIVERNET1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 52
Countries 1
Sites 12

unresectable hepatocellular carcinoma

Key facts

Sponsor
University Hospital Grenoble
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
9 Feb 2023 → ongoing
Decision date (initial)
2022-11-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

unresectable hepatocellular carcinoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

University Hospital Grenoble

2 Total trials 2 Ended
Academic / Non-commercial
Sponsor organisation
University Hospital Grenoble
Address
Boulevard De La Chantourne, Cs 10217 La Tronche, La Tronche Cs 10217 La Tronche La Tronche
City
Grenoble Cedex 9
Postcode
38043
Country
France

Scientific contact point

Organisation
University Hospital Grenoble
Contact name
Anna BOROWIK

Public contact point

Organisation
University Hospital Grenoble
Contact name
Anna BOROWIK

Locations

1 EU/EEA country · 12 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 52 12
Rest of world 0

Investigational sites

France

12 sites · Ongoing, recruitment ended
Centre Hospitalier Universitaire Grenoble Alpes
hepatogastroenterologie, Boulevard De La Chantourne, Cs 10217 La Tronche, Grenoble Cedex 9
Centre Hospitalier Universitaire D Angers
hepatogastroenterologie, 4 Rue Larrey, 49933, Angers Cedex 9
Centre Hospitalier Universitaire De Nantes
hepatogastroenterologie, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Universitaire De Toulouse
hepatogastroenterologie, Cedex 9, 2 Rue Viguerie, Toulouse
Pitie Salpetriere Hospital
hepatogastroenterologie, 47 Boulevard De L Hopital, 75651, Paris Cedex 13
Hopital Beaujon
hepatogastroentérologie, 100 Boulevard Du General Leclerc, 92110, Clichy
Centre Hospitalier Universitaire De Reims
hepatogastroenterologie, 45 Rue Cognacq Jay, 51100, Reims
Centre Léon Bérard
hepatogastroentérologie, 28 rue Laennec, cedex 08, Lyon
Centre Hospitalier Universitaire De Caen Normandie
hepatogastroenterologie, Avenue De La Cote De Nacre, Cs 30001, Caen Cedex 9
Centre Hospitalier Universitaire De Bordeaux
hepatogastroenterologie, 1 Rue Jean Burguet, 33000, Bordeaux
Hopital Saint Antoine
hepatogastroenterologie, 184 Rue Du Faubourg Saint Antoine, 75571, Paris Cedex 12
Hopital Saint Joseph
hepatogastroentérologie, 26 Boulevard De Louvain, 13008, Marseille

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2023-02-09 2023-03-15 2025-03-13

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-08-25 France Acceptable
2022-11-14
2022-11-15
2 SUBSTANTIAL MODIFICATION SM-1 2022-12-22 France Acceptable
2023-03-03
2023-03-06
3 SUBSTANTIAL MODIFICATION SM-3 2024-05-24 France Acceptable
2024-07-15
2024-08-09
4 SUBSTANTIAL MODIFICATION SM-4 2024-10-21 France Acceptable
2024-12-09
2024-12-09
5 SUBSTANTIAL MODIFICATION SM-5 2025-02-18 France Acceptable
2025-04-04
2025-04-04
6 SUBSTANTIAL MODIFICATION SM-6 2025-07-04 France Acceptable
2025-08-14
2025-08-19
7 SUBSTANTIAL MODIFICATION SM-7 2026-02-10 France Acceptable
2026-03-12
2026-03-25
8 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-22 France Acceptable
2026-03-12
2026-05-22